Paolo Guastaroba

Summary

Affiliation: University of Ferrara
Country: Italy

Publications

  1. ncbi Transradial versus transfemoral intervention for acute myocardial infarction: a propensity score-adjusted and -matched analysis from the REAL (REgistro regionale AngiopLastiche dell'Emilia-Romagna) multicenter registry
    Marco Valgimigli
    Institute of Cardiology, University of Ferrara, Ferrara, Italy
    JACC Cardiovasc Interv 5:23-35. 2012
  2. ncbi Thrombin generation assay: a new tool to predict and optimize clinical outcome in cardiovascular patients?
    Gianluca Campo
    Cardiovascular Institute, Azienda Ospedaliero Universitaria S Anna, Lumezzane, BS, Italy
    Blood Coagul Fibrinolysis 23:680-7. 2012
  3. ncbi The in vitro effects of verbascoside on human platelet aggregation
    Gianluca Campo
    Cardiovascular Institute, Azienda Ospedaliero Universitaria S Anna, Ferrara, Italy
    J Thromb Thrombolysis 34:318-25. 2012
  4. ncbi Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome
    Gianluca Campo
    Cardiovascular Institute, Azienda Ospedaliero Universitaria Sant Anna, LTTA Center, Ferrara, Italy
    J Am Coll Cardiol 57:2474-83. 2011
  5. ncbi Genetic determinants of on-clopidogrel high platelet reactivity
    Gianluca Campo
    Cardiovascular Institute, Azienda Ospedaliero Universitaria S Anna, Ferrara, Italy
    Platelets 22:399-407. 2011
  6. ncbi Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) tr
    Gianluca Campo
    Cardiovascular Institute, AOU S Anna, Ferrara, Italy
    J Am Coll Cardiol 56:1447-55. 2010
  7. ncbi Poor response to clopidogrel: current and future options for its management
    Gianluca Campo
    Cardiovascular Institute, Azienda Ospedaliera Universitaria S Anna, Ferrara, Italy
    J Thromb Thrombolysis 30:319-31. 2010
  8. ncbi Tailored medical and interventional therapy against recurrent stent thrombosis after drug-eluting stenting
    Gianluca Campo
    Cardiovascular Institute, Azienda Ospedaliera Universitaria S Anna, Ferrara, Italy
    Clin Appl Thromb Hemost 16:591-3. 2010
  9. ncbi Long-term outcome after drug eluting stenting in patients with ST-segment elevation myocardial infarction: data from the REAL registry
    Gianluca Campo
    Unita Operativa di Cardiologia, Azienda Ospedaliera Universitaria S Anna, Ferrara, Italy
    Int J Cardiol 140:154-60. 2010
  10. ncbi Percutaneous treatment of multivessel coronary disease in the drug eluting stent era: comparison of bare-metal stents, drug-eluting stents and a mixed approach in a large multicentre registry
    Elisabetta Varani
    Unita Operativa di Cardiologia, Ospedale S Maria delle Croci, Ravenna, Italy
    EuroIntervention 2:474-80. 2007

Collaborators

  • Roberto Ferrari
  • Arnoud WJ van't Hof
  • Antonio Manari
  • Manari Antonio
  • F Saia
  • Marco Balducelli
  • Luigi Vignali
  • Alberto Menozzi
  • Roberto Grilli
  • Emanuele Meliga
  • V Guiducci
  • Gianluca Campo
  • Marco Valgimigli
  • Jlenia Marchesini
  • Matteo Tebaldi
  • Luca Fileti
  • Pietro Sangiorgio
  • Antonio Marzocchi
  • Gianfranco Percoco
  • Fabio Tarantino
  • Francesco Passerini
  • Elisabetta Varani
  • Alberto Pollina
  • Rita Pavasini
  • Monia Monti
  • Paolo Magnavacchi
  • Matteo Miccoli
  • Alberto Benassi
  • Andrea Santarelli
  • Stefano Tondi
  • Massimo Giuseppe Sangiorgi
  • Laura Bristot
  • Massimo Margheri
  • Stefania Gambetti
  • Paolo Ferraresi
  • Barbara Lunghi
  • Giovanni Parrinello
  • Francesco Bernardi
  • Salvatore Colangelo
  • Filippo Russo
  • Nicoletta de Cesare
  • Alessandro Furgieri
  • Salvatore Brugaletta
  • Caterina Cavazza
  • Chiara Carrescia
  • Rossana De Palma
  • Roberto Carletti
  • Elisa Cangiano
  • Cinzia Marrozzini
  • Aleardo Maresta
  • Enrico Aurier
  • Giuseppe Geraci
  • Monica Naldi
  • Giancarlo Piovaccari

Detail Information

Publications11

  1. ncbi Transradial versus transfemoral intervention for acute myocardial infarction: a propensity score-adjusted and -matched analysis from the REAL (REgistro regionale AngiopLastiche dell'Emilia-Romagna) multicenter registry
    Marco Valgimigli
    Institute of Cardiology, University of Ferrara, Ferrara, Italy
    JACC Cardiovasc Interv 5:23-35. 2012
    ..This study sought to assess whether transradial intervention, by minimizing access-site bleeding and vascular events, improves outcomes in patients with ST-segment elevation myocardial infarction compared with the transfemoral approach...
  2. ncbi Thrombin generation assay: a new tool to predict and optimize clinical outcome in cardiovascular patients?
    Gianluca Campo
    Cardiovascular Institute, Azienda Ospedaliero Universitaria S Anna, Lumezzane, BS, Italy
    Blood Coagul Fibrinolysis 23:680-7. 2012
    ..Moreover, a brief summary of its ability to predict ischemic and bleeding risks has been provided...
  3. ncbi The in vitro effects of verbascoside on human platelet aggregation
    Gianluca Campo
    Cardiovascular Institute, Azienda Ospedaliero Universitaria S Anna, Ferrara, Italy
    J Thromb Thrombolysis 34:318-25. 2012
    ..These preliminary data, while intriguing, require confirmation in subjects receiving verbascoside orally in order to determine whether these findings are clinically relevant...
  4. ncbi Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome
    Gianluca Campo
    Cardiovascular Institute, Azienda Ospedaliero Universitaria Sant Anna, LTTA Center, Ferrara, Italy
    J Am Coll Cardiol 57:2474-83. 2011
    ..This study sought to investigate the evolving pattern over time of on-clopidogrel platelet reactivity (PR) and its relationship with genotype and clinical outcomes after percutaneous coronary intervention...
  5. ncbi Genetic determinants of on-clopidogrel high platelet reactivity
    Gianluca Campo
    Cardiovascular Institute, Azienda Ospedaliero Universitaria S Anna, Ferrara, Italy
    Platelets 22:399-407. 2011
    ..The aim of this review is to describe the principal gene polymorphisms influencing on-clopidogrel PR and their relationship with long-term clinical outcome...
  6. ncbi Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) tr
    Gianluca Campo
    Cardiovascular Institute, AOU S Anna, Ferrara, Italy
    J Am Coll Cardiol 56:1447-55. 2010
    ....
  7. ncbi Poor response to clopidogrel: current and future options for its management
    Gianluca Campo
    Cardiovascular Institute, Azienda Ospedaliera Universitaria S Anna, Ferrara, Italy
    J Thromb Thrombolysis 30:319-31. 2010
    ..This paper reviews the impact of clopidogrel poor responsiveness on clinical outcomes, the mechanisms leading to poor effect and the different assays to assess it. Finally, current and future options for its management is discussed...
  8. ncbi Tailored medical and interventional therapy against recurrent stent thrombosis after drug-eluting stenting
    Gianluca Campo
    Cardiovascular Institute, Azienda Ospedaliera Universitaria S Anna, Ferrara, Italy
    Clin Appl Thromb Hemost 16:591-3. 2010
    ....
  9. ncbi Long-term outcome after drug eluting stenting in patients with ST-segment elevation myocardial infarction: data from the REAL registry
    Gianluca Campo
    Unita Operativa di Cardiologia, Azienda Ospedaliera Universitaria S Anna, Ferrara, Italy
    Int J Cardiol 140:154-60. 2010
    ..The purpose of this study was to compare the long-term outcome of STEMI patients undergoing primary PCI with DES vs. bare metal stent (BMS) implantation...
  10. ncbi Percutaneous treatment of multivessel coronary disease in the drug eluting stent era: comparison of bare-metal stents, drug-eluting stents and a mixed approach in a large multicentre registry
    Elisabetta Varani
    Unita Operativa di Cardiologia, Ospedale S Maria delle Croci, Ravenna, Italy
    EuroIntervention 2:474-80. 2007
    ..However, this selective use of DES was independently associated with a lower incidence of 1-year TVR and MACE. Whether increasing the rate of DES utilisation would further improve the clinical outcome remains to be investigated...
  11. ncbi Safety and long-term efficacy of sirolimus eluting stent in ST-elevation acute myocardial infarction: the REAL (Registro REgionale AngiopLastiche Emilia-Romagna) registry
    Gianfranco Percoco
    Unità di Cardiologia, Universita di Ferrara, Ospedale S Anna Ferrara, Ferrara
    Cardiovasc Drugs Ther 20:63-8. 2006
    ..Limited data are available for sirolimus eluting stent (SES) implantation in patients with ST-segment elevation myocardial infarction (STEMI)...